Aditx Therapeutics (ADTX)
(Delayed Data from NSDQ)
$0.50 USD
+0.02 (4.20%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.48 -0.02 (-3.23%) 5:16 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.50 USD
+0.02 (4.20%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.48 -0.02 (-3.23%) 5:16 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Indivior PLC (INDV) delivered earnings and revenue surprises of 13.33% and 2.26%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 19.74% and 18.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 106.98% and 120.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 59.34% and 119.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
Implied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Aditxt (ADTX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aditxt (ADTX) stock based on the movements in the options market lately.